Tags : ADAURA Study

AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA

Tuba Khan September 21, 2020

Shots: The P-III ADAURA study involves assessing of Tagrisso (80mg, qd, PO) vs PBO for the adjuvant treatment of 682 patients with stage IB, II, IIIA EGFRm NSCLC following complete […]readmore

Tags : ADAURA Study

AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : ADAURA Study

AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company